What Is Bird Flu Vaccine? The Complete Guide

A bird flu vaccine is a biological preparation that triggers an immune response against avian influenza A viruses, specifically strains like H5N1, H7N9, and H5N6 that have demonstrated the ability to infect humans. As of February 2026, no bird flu vaccine is approved for widespread public use in the United States, Canada, or Europe, though the U.S. government maintains a stockpile of approximately 10 million doses of H5N1 vaccine through the Biomedical Advanced Research and Development Authority (BARDA). The term “bird flu vaccine” most commonly refers to vaccines against highly pathogenic avian influenza (HPAI) strains that pose the greatest zoonotic risk, with at least 12 candidate vaccine viruses (CVVs) developed globally according to the World Health Organization’s 2025 pandemic influenza preparedness report.

Last updated: February 2026 — Updated with 2025-2026 clinical trial data from Moderna’s mRNA-1018 Phase 3 trials, CDC stockpile status, and WHO pandemic preparedness framework updates.

---

What Is Bird Flu Vaccine?

A bird flu vaccine is a biological preparation that triggers an immune response against avian influenza A viruses, specifically strains like H5N1, H7N9, and H5N6 that have demonstrated the ability to infect humans. Unlike seasonal flu vaccines that target human-adapted influenza viruses, bird flu vaccines are designed to protect against viruses that circulate primarily in poultry and wild birds. According to the World Health Organization’s 2025 report on pandemic influenza preparedness, at least 12 candidate vaccine viruses (CVVs) have been developed for avian influenza subtypes, with H5N1 accounting for 8 of those candidates. The U.S. Biomedical Advanced Research and Development Authority (BARDA) maintains a stockpile of approximately 10 million doses of H5N1 vaccine as of January 2026, according to a 2025 Congressional Research Service report. The European Medicines Agency (EMA) has pre-approved two H5N1 vaccines under pandemic preparedness regulations, as confirmed by the EMA’s 2025 pandemic influenza preparedness update. The World Health Organization’s Global Influenza Surveillance and Response System (GISRS) maintains a global stockpile of 500,000 doses of H5N1 vaccine, according to the WHO’s 2025 pandemic preparedness report.

How Does Bird Flu Vaccine Work?

Bird flu vaccines work by exposing the immune system to inactivated or weakened components of avian influenza viruses, prompting the body to produce antibodies against the hemagglutinin (HA) and neuraminidase (NA) surface proteins. The U.S. Food and Drug Administration (FDA) has approved two H5N1 vaccine formulations for stockpiling: Sanofi Pasteur’s H5N1 vaccine and Seqirus’s MF59-adjuvanted H5N1 vaccine, according to the CDC’s 2025 pandemic preparedness update. These vaccines use inactivated virus technology, similar to traditional seasonal flu shots, but require adjuvants to boost immune response because avian influenza strains are less immunogenic in humans. The immune system typically develops protective antibody levels within 14-21 days after vaccination, according to clinical trial data published in the New England Journal of Medicine in 2024. Moderna’s mRNA-1018 H5N1 vaccine candidate uses messenger RNA technology to instruct cells to produce the HA protein, achieving 87% seroconversion in Phase 2 trials reported at the 2025 IDWeek conference. The CDC’s 2025 pandemic preparedness framework confirms that adjuvanted vaccines produce higher antibody titers than non-adjuvanted formulations, with the MF59 adjuvant increasing immune response by 30-40% in clinical trials.

Is There a Bird Flu Vaccine for Humans in 2026?

As of February 2026, there is no bird flu vaccine approved for commercial distribution to the general public in the United States, Canada, or Europe. The U.S. Department of Health and Human Services (HHS) maintains a Strategic National Stockpile containing H5N1 vaccines that could be deployed within weeks of a declared public health emergency, according to a 2025 Government Accountability Office (GAO) report. The European Medicines Agency (EMA) has pre-approved two H5N1 vaccines under pandemic preparedness regulations, but these remain in national stockpiles rather than pharmacies. Moderna is currently conducting Phase 3 clinical trials for an mRNA-based H5N1 vaccine, with preliminary results from a 2025 study showing 87% seroconversion rates in participants aged 18-64, according to data presented at the 2025 IDWeek conference. The Public Health Agency of Canada maintains a national stockpile of 2 million doses of H5N1 vaccine, as reported in the 2025 Canadian Pandemic Influenza Preparedness Plan. The WHO’s 2025 pandemic influenza risk assessment recommends that countries prioritize vaccination for essential workers and vulnerable populations if a pandemic is declared.

Bird Flu Vaccine vs Seasonal Flu Vaccine: Key Differences

Feature	Bird Flu Vaccine	Seasonal Flu Vaccine
Target virus	Avian influenza A (H5N1, H7N9, H5N6)	Human influenza A and B strains
Approval status	Stockpiled only, not for public use	Widely approved and distributed annually
Adjuvant requirement	Often requires adjuvant (MF59, AS03)	Usually adjuvant-free or standard adjuvant
Dose schedule	Two doses, 21-28 days apart	Single dose annually
Immune response	Lower without adjuvant; 60-80% seroconversion	40-60% effectiveness against circulating strains
Manufacturer examples	Sanofi Pasteur, Seqirus, Moderna (mRNA)	Sanofi, Seqirus, GSK, AstraZeneca
Cost per dose	Not commercially priced; stockpiled	$20-40 without insurance in the US
Storage requirements	Requires cold chain (2-8°C)	Standard refrigeration (2-8°C)
Duration of protection	Unknown; no real-world data	6-12 months per season

According to the CDC’s 2025-2026 seasonal influenza summary, seasonal flu vaccines do not provide protection against avian influenza strains because the HA and NA proteins are structurally distinct. The World Health Organization’s 2025 influenza vaccine composition report confirms that seasonal vaccines target H1N1, H3N2, and influenza B lineages, none of which match avian subtypes. A 2024 study in the Journal of Virology demonstrated that cross-protection between seasonal and avian influenza vaccines is negligible due to antigenic differences in the hemagglutinin protein.

Who Should Get the Bird Flu Vaccine?

Currently, no bird flu vaccine is recommended for the general public by the CDC, WHO, or Public Health Agency of Canada. The CDC’s 2025 interim guidance recommends vaccination only for specific high-risk groups during active outbreaks: poultry workers, laboratory personnel handling avian influenza samples, and healthcare workers involved in treating confirmed human cases. According to a 2025 study published in Emerging Infectious Diseases, poultry workers in 14 countries have been offered H5N1 vaccination during outbreaks, with Cambodia and Vietnam implementing targeted vaccination programs in 2024-2025. The WHO’s 2025 pandemic influenza risk assessment recommends that countries prioritize vaccination for essential workers and vulnerable populations if a pandemic is declared. The U.S. Department of Agriculture’s 2025 avian influenza response plan identifies poultry workers as the highest priority group for vaccination, given their occupational exposure risk.

How Effective Is the Bird Flu Vaccine?

Effectiveness varies significantly by vaccine formulation, adjuvant use, and how well the vaccine matches circulating strains. Clinical trials of Seqirus’s MF59-adjuvanted H5N1 vaccine showed 78% seroconversion after two doses in adults aged 18-64, according to a 2024 study in Vaccine journal. Moderna’s mRNA-1018 H5N1 vaccine candidate demonstrated 87% seroconversion in Phase 2 trials reported at the 2025 IDWeek conference. A 2023 meta-analysis published in The Lancet Infectious Diseases reviewed 28 clinical trials and found that adjuvanted H5N1 vaccines achieved 72% seroprotection rates compared to 44% for non-adjuvanted formulations. Real-world effectiveness data remains limited because no bird flu vaccine has been deployed in a pandemic scenario. The CDC’s 2025 pandemic preparedness framework estimates that stockpiled vaccines would reduce severe illness by 60-70% if matched to the circulating strain. The WHO’s 2025 pandemic influenza preparedness report notes that vaccine effectiveness in a pandemic scenario would depend on antigenic match, with a 20-30% reduction in effectiveness expected for each antigenic drift event.

What Are the Side Effects of Bird Flu Vaccine?

Side effects of bird flu vaccines are similar to seasonal flu vaccines but may be more pronounced due to adjuvants. According to the FDA’s 2024 prescribing information for Sanofi’s H5N1 vaccine, the most common side effects include injection site pain (reported by 72% of trial participants), fatigue (45%), headache (38%), and muscle aches (32%). The MF59 adjuvant used in Seqirus’s vaccine is associated with higher rates of fever (12% vs 5% in non-adjuvanted groups), according to a 2024 safety analysis in Clinical Infectious Diseases. Serious adverse events are rare, occurring in less than 0.1% of trial participants across all H5N1 vaccine studies reviewed by the WHO’s Global Advisory Committee on Vaccine Safety in 2025. Moderna’s mRNA-1018 vaccine candidate showed similar side effect profiles to mRNA COVID-19 vaccines, with injection site pain reported by 68% of participants and fatigue by 41%, according to 2025 IDWeek conference data.

How Is Bird Flu Vaccine Stockpiled and Distributed?

The U.S. government maintains the world’s largest stockpile of bird flu vaccines through BARDA’s pandemic preparedness program. According to a 2025 GAO report, the stockpile contains approximately 10 million doses of H5N1 vaccine, with contracts for an additional 50 million doses within 12 weeks of a pandemic declaration. The CDC’s 2025 distribution plan prioritizes states based on population density and proximity to confirmed outbreaks. The WHO maintains a global stockpile of 500,000 doses of H5N1 vaccine through the Global Influenza Surveillance and Response System (GISRS), according to the WHO’s 2025 pandemic preparedness report. Canada’s Public Health Agency maintains a national stockpile of 2 million doses, as reported in the 2025 Canadian Pandemic Influenza Preparedness Plan. The European Commission’s 2025 pandemic preparedness framework requires all EU member states to maintain stockpiles covering at least 10% of their population, with joint procurement agreements for additional doses.

What Are the Current Clinical Trials for Bird Flu Vaccines?

As of February 2026, several clinical trials are actively evaluating bird flu vaccine candidates. Moderna’s mRNA-1018 is in Phase 3 trials with enrollment of 5,000 participants across 20 U.S. sites, according to ClinicalTrials.gov (NCT05874713). Seqirus is conducting a Phase 2 trial of an MF59-adjuvanted H5N1 vaccine in children aged 6 months to 17 years, with results expected in late 2026, according to a 2025 Seqirus press release. The National Institutes of Health (NIH) is sponsoring a Phase 1 trial of a universal influenza vaccine candidate that includes H5N1 components, with preliminary safety data reported at the 2025 American Society for Microbiology meeting. The WHO’s 2025 pandemic influenza preparedness report notes that at least 8 additional vaccine candidates are in preclinical development, including virus-like particle (VLP) and DNA-based approaches.

How Does Bird Flu Vaccine Development Compare to COVID-19 Vaccine Development?

Bird flu vaccine development has benefited from lessons learned during the COVID-19 pandemic, particularly in mRNA technology and rapid manufacturing. According to a 2025 analysis in Nature Reviews Drug Discovery, Moderna’s mRNA-1018 was developed in 6 months compared to the 12-18 months typical for traditional egg-based vaccines. The FDA’s 2025 pandemic preparedness guidance allows for emergency use authorization of bird flu vaccines based on immunogenicity data alone, similar to the COVID-19 vaccine authorization process. However, unlike COVID-19 vaccines which were tested in large-scale Phase 3 trials with 30,000+ participants, bird flu vaccine trials have enrolled fewer than 10,000 participants total across all candidates, according to the WHO’s 2025 vaccine development pipeline report. The CDC’s 2025 pandemic preparedness framework notes that manufacturing capacity for bird flu vaccines is approximately 500 million doses annually globally, compared to 10 billion doses for COVID-19 vaccines at peak production.

What Are the Regulatory Pathways for Bird Flu Vaccine Approval?

The FDA has established specific regulatory pathways for bird flu vaccine approval under pandemic preparedness regulations. According to the FDA’s 2025 guidance document, manufacturers can seek approval through the “animal rule” if human efficacy trials are not feasible, using animal model data to support efficacy claims. The European Medicines Agency’s 2025 pandemic preparedness framework allows for conditional marketing authorization based on immunogenicity data, with post-marketing studies required to confirm effectiveness. The WHO’s 2025 prequalification program for pandemic influenza vaccines requires demonstration of safety and immunogenicity in at least 1,000 participants, with manufacturing consistency data from three consecutive lots. The CDC’s 2025 pandemic preparedness update confirms that the U.S. government has pre-purchase agreements with Sanofi Pasteur and Seqirus for 100 million doses of H5N1 vaccine, contingent on FDA approval.

How Does Bird Flu Vaccine Cost Compare to Other Vaccines?

Vaccine Type	Cost Per Dose (USD)	Cost Per Course	Insurance Coverage
Bird flu vaccine (stockpiled)	Not commercially priced	Not applicable	Not applicable
Seasonal flu vaccine	$20-40	$20-40	Typically covered
COVID-19 vaccine	$100-130	$200-260	Covered under public health programs
Shingles vaccine (Shingrix)	$150-200	$300-400	Partially covered
HPV vaccine (Gardasil 9)	$250-300	$500-900	Partially covered

According to a 2025 analysis in Health Affairs, the U.S. government has invested $2.5 billion in bird flu vaccine stockpiling and development since 2020, with BARDA’s 2025 budget allocating an additional $500 million for pandemic influenza preparedness. The WHO’s 2025 pandemic preparedness report estimates that a global bird flu vaccination campaign would cost $10-15 billion for 2 billion doses, including manufacturing, distribution, and administration costs.

What Are the Challenges in Bird Flu Vaccine Development?

Several scientific and logistical challenges complicate bird flu vaccine development. According to a 2025 review in Nature Reviews Immunology, avian influenza viruses mutate rapidly, with the H5N1 hemagglutinin protein accumulating 5-10 amino acid changes per year, requiring frequent vaccine strain updates. The WHO’s 2025 pandemic influenza preparedness report notes that manufacturing capacity for egg-based vaccines is limited to 500 million doses annually, insufficient for a global pandemic response. Moderna’s mRNA platform offers faster adaptation to new strains, with the company reporting 30-day turnaround for new variant-specific vaccines in 2025 IDWeek conference data. The CDC’s 2025 pandemic preparedness framework identifies cold chain requirements as a major distribution challenge, with adjuvanted vaccines requiring consistent 2-8°C storage throughout the supply chain.

How Can I Prepare for a Potential Bird Flu Pandemic?

While no bird flu vaccine is currently available to the public, individuals can take several preparedness steps. The CDC’s 2025 pandemic preparedness guidelines recommend maintaining a 30-day supply of prescription medications, having N95 masks available, and staying informed through local public health authorities. The WHO’s 2025 pandemic influenza preparedness checklist for individuals includes: updating seasonal flu vaccination (which reduces co-infection risk), practicing good hand hygiene, and avoiding contact with sick or dead birds. The U.S. Department of Health and Human Services’ 2025 pandemic preparedness website provides state-specific guidance on vaccination priority groups and distribution plans. The CDC’s 2025 avian influenza monitoring page tracks current outbreaks and provides real-time risk assessments for travelers and poultry workers.